Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Retained Earnings (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Retained Earnings data on record, last reported at -$707.5 million in Q3 2025.

  • For Q3 2025, Retained Earnings fell 10.67% year-over-year to -$707.5 million; the TTM value through Sep 2025 reached -$707.5 million, down 10.67%, while the annual FY2024 figure was -$650.2 million, 10.09% down from the prior year.
  • Retained Earnings reached -$707.5 million in Q3 2025 per BTAI's latest filing, down from -$676.6 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$277.3 million in Q1 2022 and bottomed at -$707.5 million in Q3 2025.
  • Average Retained Earnings over 4 years is -$538.4 million, with a median of -$590.6 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: crashed 67.47% in 2023, then fell 6.49% in 2025.
  • A 4-year view of Retained Earnings shows it stood at -$411.5 million in 2022, then tumbled by 43.51% to -$590.6 million in 2023, then fell by 10.09% to -$650.2 million in 2024, then decreased by 8.82% to -$707.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$707.5 million in Q3 2025, -$676.6 million in Q2 2025, and -$657.5 million in Q1 2025.